Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Retinal diseases are no longer a therapeutic dead end. From FDA-approved complement inhibitors for geographic atrophy to a light-based treatment that actually improves vision in dry AMD, a wave of new therapies is reshaping how ophthalmologists manage some of the most sight-threatening conditions — with more innovations on the horizon for rare diseases like Stargardt and MacTel.
Retinal disease treatment is having a moment — and it's only getting started.
Once considered largely untreatable, diseases like dry age-related macular degeneration (AMD), geographic atrophy (GA), macular telangiectasia (MacTel), and Stargardt disease now have a growing arsenal of therapies. Two FDA-approved complement inhibitors — Syfovre (pegcetacoplan, Biogen) and Izervay (avacincaptad pegol, Astellas) — can slow GA progression, while Valeda photobiomodulation (Alcon) stands out as the first treatment to demonstrate actual visual improvement in dry AMD, not just slowing of decline. Meanwhile, the PRIMA photovoltaic subretinal implant (Science Corporation) — already CE mark approved in the EU — has shown durable vision gains out to 36 months in advanced GA patients, with some even able to read full books using the device.
For rarer conditions, Encelto (revakinagene taroretcel-lwey, Alcon) is now approved for MacTel, and oral agent tinlarebant is anticipated for potential FDA approval in early 2027 for Stargardt disease type 1. Experts note that insurance coverage and access remain real-world hurdles for several of these therapies.
Key Takeaways:
Why it matters: With approximately 20 million Americans over 40 living with some form of AMD, these advances represent a meaningful shift — moving from managing inevitable decline to offering real functional improvement and, in some cases, restored reading vision.